# The Effect of Epoetin Alfa on the Anemia of Patients With Selected Cancers Receiving Chemotherapy

> **NCT00270166** · PHASE3 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 201 (actual)

## Conditions studied

- Anemia
- Multiple Myeloma
- Lymphoma
- Breast Cancer
- Ovarian Cancer
- Carcinoma, Small Cell Lung
- Esophagus Cancer
- Prostate Cancer
- Neoplasm

## Interventions

- **DRUG:** epoetin alfa

## Key facts

- **NCT ID:** NCT00270166
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1995-02
- **Primary completion:** —
- **Final completion:** 1998-05
- **Target enrollment:** 201 (ACTUAL)
- **Last updated:** 2011-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00270166

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00270166, "The Effect of Epoetin Alfa on the Anemia of Patients With Selected Cancers Receiving Chemotherapy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00270166. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*